title: Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
abstract: OBJECTIVE
  The process of metastasis requires the single tumor cell that seeds the metastatic clone to complete a complex series of steps. Identifying factors responsible for these steps is essential in developing and improving targeted therapy for metastasis. Resistance to receptor-mediated cell death, such as the Fas/Fas ligand pathway, is one mechanism commonly exploited by metastatic cell populations.
  
  
  RESULTS
  LM7, a subline of the SAOS human osteosarcoma cell line with low Fas expression, was selected for its high metastatic potential in an experimental nude mouse model. When transfected with the full-length Fas gene (LM7-Fas), these cells expressed higher levels of Fas than the parental LM7 cells or LM7-neo control-transfected cells. These cells were also more sensitive to Fas-induced cell death than controls. When injected intravenously into nude mice, the LM7-Fas cell line produced a significantly lower incidence of tumor nodules than control cell lines. Lung weight and tumor nodule size were also decreased in those mice injected with LM7-Fas. Levels of Fas were quantified in osteosarcoma lung nodules from 17 patients. Eight samples were Fas negative, whereas the remaining 9 were only weakly positive compared with normal human liver (positive control).
  
  
  CONCLUSIONS
  Our results demonstrate that altering Fas expression can impact the metastatic potential of osteosarcoma cells. We conclude that the increase of Fas on the surface of the LM7 osteosarcoma cells increased their sensitivity to Fas-induced cell death in the microenvironment of the lung, where Fas ligand is constitutively expressed. Thus, loss of Fas expression is one mechanism by which osteosarcoma cells may evade host resistance mechanisms in the lung, increasing metastatic potential. Fas may therefore be a new therapeutic target for osteosarcoma.
authors.affiliation: Division of Pediatrics, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Lafleur
authors.forename: Nadezhda V
authors.initials: NV
authors.lastname: Koshkina
authors.forename: John
authors.initials: J
authors.lastname: Stewart
authors.forename: Shu-Fang
authors.initials: SF
authors.lastname: Jia
authors.forename: Laura L
authors.initials: LL
authors.lastname: Worth
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Duan
authors.forename: Eugenie S
authors.initials: ES
authors.lastname: Kleinerman
mesh_terms: D000818:Animals; D017209:Apoptosis; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D051379:Mice; D008819:Mice, Nude; D012516:Osteosarcoma / Q000378:metabolism* / Q000473:pathology; D013936:Thymidine / Q000378:metabolism; D019014:fas Receptor / Q000378:metabolism*
chemical_list: D019014:fas Receptor; D013936:Thymidine